Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1998, for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The Company manufactures scientific instruments for trace organic compound determination and provides laboratory services, consulting, and research. The fiscal year ends September 30.
Key Financial Metrics
| Metric | Q1 1999 (Ended Dec 31, 1998) | Q1 1998 (Ended Dec 31, 1997) |
|---|---|---|
| Total Revenue | $4,598,000 | $4,330,000 |
| Gross Profit | $2,096,000 | $2,483,000 |
| Operating Income | $18,000 | $324,000 |
| Net Income (Loss) | $(6,000) | $196,000 |
| Cash and Cash Equivalents (End of Period) | $437,000 | $3,667,000 |
| Net Cash Used by Operating Activities | $(601,000) | $461,000 |
| Lines of Credit Outstanding | $950,000 | $0 |
| Total Debt (Current + Long-term) | $2,364,000 | $5,067,000 |
Margins: Gross margin decreased to approximately 45.6% from 57.3%. Operating margin contracted significantly to 0.4% from 7.5%.
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue increased 6.2% to $4.6 million. This was driven by a 36.5% increase in services revenue ($2.3M vs $1.7M), partially offset by a 13.1% decline in product revenue ($2.3M vs $2.6M) due to reduced sales in Asia.
- Profitability Decline: Net income turned to a loss of $6,000 compared to $196,000 in the prior year. Operating income dropped to $18,000 from $324,000.
- Cost Increases: Total cost of revenue rose 35.5% to $2.5 million, primarily due to the acquisition of a UK services unit and increased staffing levels. Cost of services revenue as a percentage of revenue increased to 67.5% from 53.1%.
- Cash Flow Deterioration: Operating cash flow swung from a positive $461,000 to a negative $601,000. This was driven by a net loss, a significant reduction in accounts payable ($876,000 decrease), and increased capital expenditures ($1.05M).
- Liquidity: Cash balances decreased by $771,000 to $437,000. The Company utilized $950,000 of its $7.5 million line of credit.
Outlook, Risks, and Management Commentary
- Capital Expenditures: The Company anticipates increased capital expenditures for the remainder of fiscal 1999 for facility renovations and laboratory equipment purchases.
- Liquidity Position: Management believes cash from operations and the existing $7.5 million line of credit (expiring March 1, 1999) will be sufficient to fund working capital and capital needs. The Company is negotiating to refinance the line of credit.
- Legal Contingency: CMA Microdialysis Holding A.B. has sued the Company alleging patent infringement regarding microdialysis probes. The Company denies infringement and asserts the patent is invalid. While management believes the outcome will not be materially adverse, legal expenses have negatively impacted earnings. Sales of the implicated product represent less than 1% of revenue.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks to strategic plans, profitability, and growth strategies.
Investor Verification Checklist
- Refinancing Status: Verify the outcome of negotiations to refinance the $7.5 million line of credit expiring March 1, 1999.
- Operating Cash Flow: Monitor the sustainability of negative operating cash flow and the ability to service debt without further equity dilution.
- Legal Proceedings: Track the status of the CMA Microdialysis patent infringement lawsuit and associated legal costs.
- Product Revenue Recovery: Assess whether product revenue can recover from the decline attributed to Asian currency issues.
- Service Margin Stability: Evaluate if the high cost of services revenue (67.5%) can be reduced as the acquired UK unit matures.